Rankings
▼
Calendar
RIGL Q2 2025 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
RIGL
Rigel Pharmaceuticals, Inc.
$541M
Q2 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$102M
+176.0% YoY
Gross Profit
$97M
95.6% margin
Operating Income
$61M
60.1% margin
Net Income
$60M
58.6% margin
EPS (Diluted)
$3.28
QoQ Revenue Growth
+90.7%
Cash Flow
Operating Cash Flow
$31M
Free Cash Flow
$31M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$207M
Total Liabilities
$125M
Stockholders' Equity
$82M
Cash & Equivalents
$53M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$102M
$37M
+176.0%
Gross Profit
$97M
$34M
+185.5%
Operating Income
$61M
$447,000
+13569.6%
Net Income
$60M
-$1M
+5887.7%
Revenue Segments
Gross product sales
$80M
49%
Product sales, net
$59M
36%
Contract revenues from collaborations
$43M
26%
Milestone
$3M
2%
Discounts and allowances
-$21M
-13%
← FY 2025
All Quarters
Q3 2025 →